The study, which enrolled 102 patients in China and Australia, identified 360 μg/kg as the recommended Phase 2 dose. This dosage demonstrated rapid, deep, and durable responses, particularly in heavily pretreated individuals and those with high-risk features like extramedullary disease. Among participants who achieved a complete response or better, the minimal residual disease negativity rate reached 100%.

IBI3003 is engineered to mitigate tumor escape—a common challenge when targeting a single antigen—by simultaneously engaging two distinct tumor markers alongside CD3 for T-cell activation. Safety data from the trial showed a manageable profile, with cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome cases remaining at Grade 1-2 levels. Professor Peng Liu of Zhongshan Hospital noted that the dual-target approach addresses significant clinical gaps for patients who have exhausted traditional therapies like proteasome inhibitors and immunomodulatory drugs. Innovent has already initiated a Phase 3 study, TriadicMM-1, to further evaluate the antibody's efficacy against standard treatment options.